X4 Pharmaceuticals (XFOR) Stock Price, News & Analysis

Company Overview

X4 Pharmaceuticals, Inc. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule modulators of G protein-coupled receptors (GPCRs). The company’s research emphasizes the SDF-1/CXCR4 axis and other GPCR targets to regulate cell trafficking and immune response. X4’s technology platform is designed to address unmet needs in oncology, immunology and rare diseases by selectively modulating receptor activity.

The lead candidate in X4’s pipeline, X4P-001, is being developed as a therapeutic agent to mobilize hematopoietic stem cells for transplantation and to enhance immune-oncology regimens. Additional programs include X4P-202, a selective sphingosine-1-phosphate receptor modulator with potential applications in pulmonary arterial hypertension and autoimmune disorders, and X4P-003, targeting rare immunological diseases. These programs are advancing through preclinical and early clinical stages with a goal of demonstrating safety and efficacy in well‐defined patient populations.

Founded as a spin-out from GlycoMimetics in 2020 and headquartered in Cambridge, Massachusetts, X4 Pharmaceuticals leverages both in‐house expertise and external collaborations to accelerate development. The company maintains research activities in the United States and Europe and has established partnerships with academic institutions and contract research organizations to support its preclinical and clinical efforts.

Under the leadership of President and Chief Executive Officer Monee C. McGrath, X4 Pharmaceuticals has assembled a management team with deep experience in drug discovery, clinical development and regulatory affairs. The company’s strategic focus on novel GPCR modulators positions it to deliver differentiated therapies aimed at improving outcomes for patients with serious and underserved diseases.

Key Stats

• Today's Range: $1.63 to $1.79
• 50-Day Range: $1.66 to $4.30
• 52-Week Range: $1.63 to $26.96
• Volume: 594,569 shs
• Average Volume: 138,028 shs
• Market Capitalization: $9.61 million
• P/E Ratio: 0.77
• Dividend Yield: N/A
• Price Target: $72.33
• Consensus Rating: Buy

X4 Pharmaceuticals Stock Analysis - MarketRank™

X4 Pharmaceuticals scored higher than 93% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

X4 Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

X4 Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for X4 Pharmaceuticals are expected to grow in the coming year, from ($0.68) to ($0.51) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of X4 Pharmaceuticals is 0.77, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.91.

Price to Earnings Ratio vs. Sector

The P/E ratio of X4 Pharmaceuticals is 0.77, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 28.00.

Price to Book Value per Share Ratio

X4 Pharmaceuticals has a P/B Ratio of 0.43. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

12.63% of the float of X4 Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

X4 Pharmaceuticals has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in X4 Pharmaceuticals has recently increased by 22.15%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

X4 Pharmaceuticals does not currently pay a dividend.

Dividend Growth

X4 Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.6 / 5
• Environmental Score: -0.85

Percentage of Shares Shorted

12.63% of the float of X4 Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

X4 Pharmaceuticals has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in X4 Pharmaceuticals has recently increased by 22.15%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for X4 Pharmaceuticals this week, compared to 2 articles on an average week.

Search Interest

Only 4 people have searched for XFOR on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

6 people have added X4 Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, X4 Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $2,559.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 2.37% of the stock of X4 Pharmaceuticals is held by insiders.

Percentage Held by Institutions

72.03% of the stock of X4 Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

XFOR Stock Analysis - Frequently Asked Questions

How have XFOR shares performed this year?

X4 Pharmaceuticals' stock was trading at $22.0080 on January 1st, 2025. Since then, XFOR shares have decreased by 92.5% and is now trading at $1.66.

How were X4 Pharmaceuticals' earnings last quarter?

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) released its quarterly earnings results on Thursday, May, 1st. The company reported $0.04 earnings per share for the quarter, beating the consensus estimate of ($4.13) by $4.17. The business earned $28.81 million during the quarter, compared to analyst estimates of $7.03 million. X4 Pharmaceuticals had a negative trailing twelve-month return on equity of 181.56% and a net margin of 46.54%.
Read the conference call transcript.

When did X4 Pharmaceuticals' stock split?

X4 Pharmaceuticals shares reverse split on the morning of Monday, April 28th 2025.The 1-30 reverse split was announced on Thursday, April 24th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Friday, April 25th 2025. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

How do I buy shares of X4 Pharmaceuticals?

Shares of XFOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of X4 Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that X4 Pharmaceuticals investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Intel (INTC).

Company Calendar

• Last Earnings: 5/01/2025
• Today: 7/09/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:XFOR
• CIK: 1501697
• Web: www.x4pharma.com
• Phone: (857) 529-8300
• Fax: N/A
• Employees: 80
• Year Founded: N/A

Price Target and Rating

• Average Price Target for X4 Pharmaceuticals: $72.33
• High Price Target: $120.00
• Low Price Target: $7.00
• Potential Upside/Downside: +4,257.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): $2.14
• Trailing P/E Ratio: 0.77
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$37.45 million
• Net Margins: 46.54%
• Pretax Margin: 47.58%
• Return on Equity: -181.56%
• Return on Assets: -54.36%

Debt

• Debt-to-Equity Ratio: 3.30
• Current Ratio: 3.70
• Quick Ratio: 3.58

Sales & Book Value

• Annual Sales: $2.56 million
• Price / Sales: 3.75
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.90 per share
• Price / Book: 0.43

Miscellaneous

• Outstanding Shares: 5,790,000
• Free Float: 5,652,000
• Market Cap: $9.61 million
• Optionable: Optionable
• Beta: 0.54